Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry

被引：0

作者：

Ogdie, Alexis ^{[1
]}

Song, Chao ^{[2
]}

Middaugh, Nicole ^{[3
]}

Marchese, Maya ^{[3
]}

Eliot, Melissa ^{[3
]}

Low, Robert ^{[2
]}

Mease, Philip ^{[4
,5
]}

机构：

[1] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA USA

[2] UCB Pharma, Smyrna, GA USA

[3] CorEvitas LLC, Waltham, MA USA

[4] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[5] Univ Washington, Sch Med, Seattle, WA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

0581

引用

页码：1177 / 1180

页数：4